Gilead Sciences, Inc. - Investor Relations
WEBInvestor Relations. At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in.
Gilead Sciences, Inc. - Gilead Sciences Announces Fourth Quarter …
WEBFeb 6, 2024 · HIV product sales increased 6% to $18.2 billion in the full year 2023 compared to 2022, primarily reflecting higher demand across treatment and prevention, in addition to higher average realized price and favorable channel inventory dynamics.
Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Present at Upcoming Investor Conferences; April 26, 2024 FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV; April 25, 2024 Gilead Sciences Announces First Quarter 2024 Financial Results
Gilead Sciences Announces Fourth Quarter and Full Year 2021 …
WEBFeb 1, 2022 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021.
WEBAug 3, 2023 · Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
Gilead Sciences Announces First Quarter 2022 Financial Results
WEBApr 28, 2022 · Announced that the company’s Board of Directors declared a quarterly dividend of $0.73 per share of common stock for the second quarter of 2022. The dividend is payable on June 29, 2022, to ...
Gilead Sciences, Inc. - Financials - Quarterly Results
WEBFinancial summary table containing documents grouped by year, quarter and type.
Gilead Sciences Announces First Quarter 2024 Financial Results
WEBApr 25, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology …
GILD Stock - Gilead Sciences Inc Stock Price - NASDAQ
WEBSee the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.
GILD | Gilead Sciences Inc. Financial Statements - WSJ
WEBGilead Sciences Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View GILD financial statements in full.
- Some results have been removed